Cargando…

Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs

The incidence and prevalence of inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, have increased in Asia and developing countries. In the past two decades, anti-tumor necrosis factor (TNF) agents have revolutionized the treatment of IBD, in part by decreasing the r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Na, Soo-Young, Kim, You Sun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association of Internal Medicine 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449214/ https://www.ncbi.nlm.nih.gov/pubmed/35945034 http://dx.doi.org/10.3904/kjim.2022.152

Ejemplares similares

Small Molecule Drugs in Inflammatory Bowel Diseases
por: Ben Ghezala, Inès, et al.
Publicado: (2021)

Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
por: Pagnini, Cristiano, et al.
Publicado: (2019)

Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors
por: Crispino, Federica, et al.
Publicado: (2023)

New biologics and small molecules in inflammatory bowel disease: an update
por: Sabino, João, et al.
Publicado: (2019)

Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease
por: Xu, Yi-Han, et al.
Publicado: (2022)

Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases
por: Khoshnam-Rad, Niloofar, et al.
Publicado: (2023)

Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
por: Evangelatos, Gerasimos, et al.
Publicado: (2020)

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases
por: Reinglas, Jason, et al.
Publicado: (2018)

Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease
por: Balderramo, Domingo
Publicado: (2022)

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies
por: Dulai, Parambir S., et al.
Publicado: (2019)

Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease
por: Jun, Yu Kyung, et al.
Publicado: (2023)

Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies
por: Cheah, Eric, et al.
Publicado: (2023)

Anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Ramakrishna, B.S.
Publicado: (2017)

Study of tumor necrosis factor receptor in the inflammatory bowel disease
por: Souza, Roberta Figueiroa, et al.
Publicado: (2023)

Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2021)

Breaking the Therapeutic Ceiling: Dual Biologic or Small Molecule Therapy for Refractory Inflammatory Bowel Disease
por: Ahmed, Waseem
Publicado: (2022)

Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease
por: Bilal, Muhammad, et al.
Publicado: (2021)

Small bowel necrosis after esophagectomy
por: Shao, Longlong, et al.
Publicado: (2023)

Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
por: Alayo, Quazim A, et al.
Publicado: (2022)

Effectiveness of Dual Biologic or Small Molecule Therapy for Achieving Endoscopic Remission in Refractory Inflammatory Bowel Disease
por: Abdullah, Israa, et al.
Publicado: (2022)

An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease
por: Patel, Rajan N., et al.
Publicado: (2020)

Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease
por: Gareb, Bahez, et al.
Publicado: (2020)

Explore Small Molecule-induced Genome-wide Transcriptional Profiles for Novel Inflammatory Bowel Disease Drug
por: Cai, Xiaoshu, et al.
Publicado: (2016)

Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
por: Lee, Jang Wook, et al.
Publicado: (2016)

Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics
por: Li, Ping, et al.
Publicado: (2017)

Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond
por: Davidson, David, et al.
Publicado: (2013)

Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature
por: Kothari, Mansi M, et al.
Publicado: (2017)

The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Fousekis, Fotios S., et al.
Publicado: (2022)

Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
por: Marsal, Jan, et al.
Publicado: (2022)

Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
por: Kim, Ju Young, et al.
Publicado: (2021)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

Dendritic Cell Profiles in the Inflamed Colonic Mucosa Predict the Responses to Tumor Necrosis Factor Alpha Inhibitors in Inflammatory Bowel Disease
por: Smrekar, Natasa, et al.
Publicado: (2018)

Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature
por: Grillo, Thais Gagno, et al.
Publicado: (2023)

Association of Tumor Necrosis Factor Alpha Gene Polymorphisms with Inflammatory Bowel Disease in Iran
por: NADERI, Nosratollah, et al.
Publicado: (2014)

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
por: Billmeier, Ulrike, et al.
Publicado: (2016)

Association of tumor necrosis factor-α and -β gene polymorphisms in inflammatory bowel disease
por: Al-Meghaiseeb, Ebtissam Saleh, et al.
Publicado: (2016)

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)

Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease
por: Abdullah, Israa, et al.
Publicado: (2021)

The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers
por: Byun, Ja Min, et al.
Publicado: (2015)

Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study
por: Goessens, Laurent, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5grh0coe86u2mej482qsanf1t6